340 related articles for article (PubMed ID: 15683730)
1. Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways.
Taylor C; Fricker AD; Devi LA; Gomes I
Cell Signal; 2005 May; 17(5):549-57. PubMed ID: 15683730
[TBL] [Abstract][Full Text] [Related]
2. [The neuroendocrinology of stress and the pathophysiology and therapy of depression and anxiety].
Ströhle A
Nervenarzt; 2003 Mar; 74(3):279-91; quiz 292. PubMed ID: 12627245
[TBL] [Abstract][Full Text] [Related]
3. [The role of the hypothalamo-hypophyseal-adrenocortical system in the specific activity of antidepressive agents].
Arushanian EB; El'bek'ian KS
Eksp Klin Farmakol; 1995; 58(3):65-70. PubMed ID: 7663305
[TBL] [Abstract][Full Text] [Related]
4. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders.
Ressler KJ; Nemeroff CB
Depress Anxiety; 2000; 12 Suppl 1():2-19. PubMed ID: 11098410
[TBL] [Abstract][Full Text] [Related]
5. Long-term anxiolytic and antidepressant-like behavioural effects of tiagabine, a selective GABA transporter-1 (GAT-1) inhibitor, coincide with a decrease in HPA system activity in C57BL/6 mice.
Thoeringer CK; Erhardt A; Sillaber I; Mueller MB; Ohl F; Holsboer F; Keck ME
J Psychopharmacol; 2010 May; 24(5):733-43. PubMed ID: 19346277
[TBL] [Abstract][Full Text] [Related]
6. Curcumin as a putative antidepressant.
Seo HJ; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Pae CU
Expert Rev Neurother; 2015 Mar; 15(3):269-80. PubMed ID: 25644944
[TBL] [Abstract][Full Text] [Related]
7. Invited review: the evolution of antidepressant mechanisms.
Slattery DA; Hudson AL; Nutt DJ
Fundam Clin Pharmacol; 2004 Feb; 18(1):1-21. PubMed ID: 14748749
[TBL] [Abstract][Full Text] [Related]
8. Antidepressants. Current concepts of mode of action.
Léonard BE
Encephale; 1991; 17 Spec No 1():127-31. PubMed ID: 1677887
[TBL] [Abstract][Full Text] [Related]
9. New approaches to antidepressant drug discovery: beyond monoamines.
Berton O; Nestler EJ
Nat Rev Neurosci; 2006 Feb; 7(2):137-51. PubMed ID: 16429123
[TBL] [Abstract][Full Text] [Related]
10. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders.
Morilak DA; Frazer A
Int J Neuropsychopharmacol; 2004 Jun; 7(2):193-218. PubMed ID: 15003145
[TBL] [Abstract][Full Text] [Related]
11. New drug targets in the signaling pathways activated by antidepressants.
Páez-Pereda M
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):1010-6. PubMed ID: 15946780
[TBL] [Abstract][Full Text] [Related]
12. [Mechanism of action of antidepressants and therapeutic perspectives].
Bourin M; David DJ; Jolliet P; Gardier A
Therapie; 2002; 57(4):385-96. PubMed ID: 12422559
[TBL] [Abstract][Full Text] [Related]
13. [Neurobiological mechanisms of depression and antidepressant therapy].
Shishkina GT; Dygalo NN
Zh Vyssh Nerv Deiat Im I P Pavlova; 2010; 60(2):138-52. PubMed ID: 20469588
[TBL] [Abstract][Full Text] [Related]
14. Increasing Adult Hippocampal Neurogenesis is Sufficient to Reduce Anxiety and Depression-Like Behaviors.
Hill AS; Sahay A; Hen R
Neuropsychopharmacology; 2015 Sep; 40(10):2368-78. PubMed ID: 25833129
[TBL] [Abstract][Full Text] [Related]
15. Vasopressin antagonists as anxiolytics and antidepressants: recent developments.
Simon NG; Guillon C; Fabio K; Heindel ND; Lu SF; Miller M; Ferris CF; Brownstein MJ; Garripa C; Koppel GA
Recent Pat CNS Drug Discov; 2008 Jun; 3(2):77-93. PubMed ID: 18537767
[TBL] [Abstract][Full Text] [Related]
16. Novel agents in development for the treatment of depression.
Grady MM; Stahl SM
CNS Spectr; 2013 Dec; 18 Suppl 1():37-40; quiz 41. PubMed ID: 24252548
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant-like activity of a Kampo (Japanese herbal) medicine, Koso-san (Xiang-Su-San), and its mode of action via the hypothalamic-pituitary-adrenal axis.
Ito N; Nagai T; Yabe T; Nunome S; Hanawa T; Yamada H
Phytomedicine; 2006 Nov; 13(9-10):658-67. PubMed ID: 16516452
[TBL] [Abstract][Full Text] [Related]
18. QCM-4, a 5-HT₃ receptor antagonist ameliorates plasma HPA axis hyperactivity, leptin resistance and brain oxidative stress in depression and anxiety-like behavior in obese mice.
Kurhe Y; Mahesh R; Devadoss T
Biochem Biophys Res Commun; 2015 Jan; 456(1):74-9. PubMed ID: 25446100
[TBL] [Abstract][Full Text] [Related]
19. Monoamine neurocircuitry in depression and strategies for new treatments.
Hamon M; Blier P
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
[TBL] [Abstract][Full Text] [Related]
20. The neurobiology of depression and antidepressant action.
Willner P; Scheel-Krüger J; Belzung C
Neurosci Biobehav Rev; 2013 Dec; 37(10 Pt 1):2331-71. PubMed ID: 23261405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
